Grow derm sales team by 25% and then get a CRL for Duobrii, one of the "significant seven," apparently the seven drugs that are going to turn around Valeant. Don't bother with the fact that combined all of those drugs bring in less than $100 million in revenue. But they will generate over $1 billion within 5 years.

Oh boy! I've heard that before!!!

Papa's response -

"We are working to resolve this matter expeditiously and have already requested a meeting with the FDA," Valeant CEO Joseph Papa said in a statement.

Real response -

Maybe we didn't need the extra 25% derm reps.